Analyst Conference Summary

Bind Therapeutics
BIND

conference date: May 7, 2015 at 5:30 A.M. Pacific Time
for quarter ending: March 31, 2015 (Q1, first quarter 2015)


Forward-looking statements

Note: this is the first time I will be covering BIND, which I first bought on 4/20/2015, but it has been on my watch list for quite a while.

Overview: Progress continues to be made on the pipeline of this development stage biotechnology company.

Basic data (GAAP):

Revenue was $4.4 million, up from $1.6 millon year-earlier.

Net income was negative $8.6 million, flat from year-earlier.

EPS diluted was negative $0.44, up from $0.51 year-earlier.

Guidance:

none

Conference Highlights:

BIND has collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd. and Merck & Co., or Merck to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. Bind also has proprietary, unpartnered programs.

The lead candidate is BIND-014, an Accurin that contains docetaxel, for prostate cancer. Bind is now enrolling patients in a Phase 2 trial for non-small cell lung cancer with KRAS mutations and squamous histology. Another Phase 2 trial in multiple tumor types will begin this quarter. First data readouts could come before the end of 2015.

In collaboration with AstraZeneca AZD2811 should go into Phase 1 in the second half of 2015. Positive pre-clinical data was presented at the AACR meeting.

The company hopes to finish BIND-510 preclinical studies this year and file for an IND in 2016.

See also the Bind Therapeutics Pipeline page

Revenue in the quarter was from reimbursement of R&D expenses by partners and from partial recognition of license fee and milestone revenue. A $1 million milestone from AstraZeneca was reached in the quarter.

Cash balance ended at $63 million and cash should last through the first half of 2016, or longer if milestone payments are received. Long term debt was $13.4 million and warrant liability was $7.6 million.

Operating expenses of $12.9 million consisted of $8.2 million for research and development and $4.8 million for general and administrative. Loss from operations was $8.6 million.

Q&A:

Enrollment and PD-1 failures? The trial is a second line trial, so that has not been an issue for the KRAS cohort. We will keep a close eye on patient accruals in the squamous cohort.

In the Insight 2 trial of four tumor types, we will enroll in the U.S. and Russia, and we expect to have data from at least 20 patients in at least 2 tumor types by the first quarter of next year.

Reduction of toxicity in AstraZeneca trial? The Aurora B kinase inhibitor has bone marrow toxicity, which we have eleminated in pre-clinical models. The drug itself was not seen as a good candidate because of its toxicity.

How large of a payload can Accurins carry? The sweet spot is about 100 nanometers. The larger the molecule carried, the less molecules can be carried, so you get a lower concentration.

OpenIcon Analyst Conference Summaries Main Page

 

Search

More Analyst Conference Pages:

 ADEP
 AGEN
 AKAM
 ALTR
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CELG
 CMN
 GILD
 HILL
 INTC
 HNSN
 INO
 ISRG
 MACK
 MCHP
 MRVL
 MYL
 NVDA
 RHT
 REGN
 STX
 SGEN
 SGI
 TTMI
 VRTX
 XLNX

 

Disclaimer: My analyst call summaries may include both our condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2015 William P. Meyers